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D908168 Differential Regulation of Ventricular ANPand
BNP synthesis in Compensated snd Overt Heart
Faiiure
R. Wlllenbrock, T. Langenickel, L Pagel, K. H6hnel, M. Scheuermann,
R. Dietz. Franz-Volhar&C//nic,HumboldtUnhwsi~,Berlin,Germany
Under physiological conditions the atrfal natriuretic peptide (ANP) is synthe-
sized in the atria while brain natriuretic peptide (BNP) is produced mainly in
theventriclea. Tha differential regulation of mRNA induction of ANP and BNP
is not well studied. The aim of this study was to analyse the induction of ven-
tricular mRNA for both peptides in two models of experimental hypettrophy
and heart failure. We induced compensated hypettrophy by a small infrarenal
aortocaval shunt and overi heari failura by a large ahunt in adult Wistar rats.
mRNA was measured by hybridisation with specific probes for ANP and
BNP in Northern Blot and Slot blot technique. All data were normalised to
GAPDH mRNA expression. In the compensated hypertrophy model ANP
plasma levels increased and significant cardiac hypertrophy developed in
all heart chambers. No hemodynamic alteration occurred. The overt heari
failure model was characterized by further elevated ANP plasma Ievela,
decreased cardiac contractility (dP/dt max), elevated enddiaatolic presaure,
increased lung weight and highar mortality. In compensated hypertrophy left
ventricular ANP-mRNA expression was induced four-foid (1.1 + 0.1 to 4.8
+ 0.7, arbitrary units, AU, p < 0.01) while BNP-mRNA expression was not
different from controls. In contrast, in overt heart failure, BNP-mRNA levels
increased significantly (0.7 + 0.1 to 2.9 + 0.4 AU, p c 0.01) whiie ventricular
ANP expression did not increase funher. Our data Indicate that the maximal
induction of ventricular ANP-mRNA wasalready achieved in compensated
hypertrophy while ventricular BNP-mRNA expression was only induced in
overt heart failure. BNP seems to be a more specific marker of severe heart
failure.
1908-169] DiffersrntiaiReguiation of CircuiatingAtrisi
Natriuretio Peptide and Brain Natriuretic Peptide
by Endogenous Endotheiin During the
Progression of Experimental Heart Faiiure
D.D. Borgeson, J.A. Grantham, E. Williamson, M.M. Radfield, A. Luchnar,
T.J. Opgenorth, J.C. Burnett, Jr. Cardiorena/ResearchLaboratow,Mayo
Clinic,RochestecMN,USA
While studias have established that mechanical stretch and humoral stim-
ulation enhances ANP and BNP syntheais andlor releaae, in vitro studies
suggest that ANP and BNP are differentially regulated and may be respon-
sive to stimulation by endothelin-1 (ET). We tested the hypothesis that ET
increasea circulating ANP and BNP during the progression of CHF, indepen-
dent of increases in cardiac filling pressures via the ET-A receptor subtype.
We determined circulating ANP and BNP during the progression of experi-
mental CHF produced by 21 days of rapid ventricular pacing in the presance
and abaenea of oral administration of an ET-A selective receptor antagonist
(A-127722, Abbott Pharmaceuticals, 5 mgikgbid PO).
ET pg/ml ANP, pg/ml BNP, pgrml RAP, mmHg PCWP mmHg
Untreated
Baseline 4.3 * 1,3 52& 16 35• 10 5.8 l 0.5 10.2 i 0.5
14 Days t4.4 +2aJ 1070 + 197a) 152+ 35’) 15.2 + 1.4a) 26,3+ 0.9aJ
21 Days 10.9 + 1.7a) 970+ 107aJ 256 + 438) 19.6 + OSa) 33,2 + 1.7aJ
Trested
Baseline 11,7+ 2.2b) 42+9 42+ 10 4.6 + 0.5 10.7+ 1.1
14 Days 17.4 l 2.s 276 +79b) 261 +62 15.9+ o.9al 25.6+ l.la)
21 Dsys 1S.9 + 6.5 346 + 93abJ 243 + 73a) 16.5 + 1.5aJ 28.3 + 1.5abJ
a) p <0.05 Vs Bsseline;b) p <0.05 Untrestedvs Trested
Thus chronic ET-A receptor antagonism in experimental CHF markedly
attenuated the increase in circulating ANP but not BNP in the absence of a
reduction in the increaae in cardiac filling presaures. These studias suggest
differential regulation of plasma ANP and BNP during the evolution of CHF
in which the increaae in circulating ANP, but not BNP is linked to the ET-A
receptor.
m908170 Long-term Effects of a High-Doae of TheEndotheiin Antagonist Boeentan in a Rat Modei of
Chronic Hesrt Faiiure
P.Mulder, M. Hogie, V. Richard, J.-P. Henry,J.-P. Clozel, C. Thuillez.
Depafimentof Pharmacology(VACOMED,lFRMPnQ23),RouenUniv.
M&. School,France
Haarl failure (HF) iacharacterizad by an increasa in plasma and tissua levels
of endothelin (ET). Blockade of its effects might be beneficial in HF. We
have previously shown that the ETA-ETs antagonist bosentan (Boa), at the
dose of 30 mg.kg-i day-i had no effect on survival or hemodynamics in a
rat model of HF [1], perhaps due to insufficient ET-receptor blockade. Thus,
we investigated the effects of a 6 month treatment with Bos, at the dose of
100 mg.kg-l day-l, on survival and ayatemic hemodynamics and mmpared
these effects to those of the ACE inhibitor cilazapril (Cil; 10 mg.kg-l day-l).
HF was inducad in rats by corona~ artery ligation and treatments were given
aa food admix, starting 7 days after ligation (n =52 par group). After 1, 3 and
6 months, systolic blood pressure (SBP) and heari rate (HR) were measured
in conscious rats. Table shows survival after 6 months, SBP and HR (*p c
0,05 vs HF; tp <0,05 VS 60s).
$uwivsl(%) SBP (mm Hg) HR (btsrmln)
1 3 6 1 3 6
HF 64 112* 1 lt7+ 2 119 + 1 398+8 40S + 8 425+5
HF + 60s 89* 109+2 IOe& 7* 112 + 1“ 374+7* 371 +8* 382+5’
HF + Cil 87* 80 h 2*t 80+ l’t 75+ l’t 393&6 369&7* 395&8*
Thus, Bos, at the dose of 100 mg.kg-’ day-i, improves sutvival to the
same extent as Cil. Although Bos reduces 56P less than Cil, both induce
similar, significant decreases in HR. These results demonstrate for the first
time that ETantagoniata improve survival in HF and suggest that these drugs
may be beneficial in this pathology.
[1] Mulder et al., JACC, 27,258, 1996.
908-171 Brain Natriuretic Peptide improves Diaetoiie
Function in the Normal and Faiiing Heart
K. Yamamoto, J.C. Bumatt, Jr., M.M. Redfield. MayoC//n/c,i%oheste~MN,
USA
Brain natriuretic peptide (EfNP) is the most potently natriuretic member of
the natriuratic peptide family, is a sensitive and specific marker of altered
LV structure and function and is being developed es a therapeutic agent for
heart failure (HF). As receptors for BNP are present on the myoeyte, wa
hypothesized that BNP may modulate ventricular function via activation of
ita aecond meaaenger, cGMP. To elucidate the effects of exogenous BNP
on LV function in the normal heart and to determine if the actions of BNP
are maintained in the presence of HF, an intraooronary infueion of BNP (25
rrg/k~min x 30 reins) was used to avoid systemic effects in 6 normal (N)
dogs and in 9dogs with chronic HF induced by rapid ventrfcularpacing. Heart
rate was controlled by atrial pacing during the infusion.
Resu/ts:(mean + SD, ‘ p <0.05 vs Control, Tau = the time constant of
LV relaxation, t = the time to the oneet of LV relaxation)
N HF
Control BNP Control BNP
LVSP (mmHg) 112 *s 111k5 95• 12 93* 11
LVEDP (mmHg) 6*6 4*4 10+6 10+6
Tsu (ins) 31 * s 24 &8* 77• 44 63 *43*
t (ins) 196+22 163* 27* 237 &21 233 %23
himitccrit (%) 43•2 44* 2 37*5 37*5
In both N and HF doga, BNP accelerated the rate of LV relaxation without
changes in LVEDP or hamatocrit to suggest deereasaa in venous return.
Peak + dP/dt did not incraase. In N dogs the time to onset of LV relaxation
was also shortened. We conclude that BNP has a specific effect to improve
LV relaxation which is unassociated with a positive inotropic effect and which
is maintained in HF. As impaired relaxation contribute to deterioration of
hemodynamica with exerciae in HF, the specific “lusitropic” action of BNP
represents a potentially important therapeutic action of this peptide.
[908-1721 DifferentiaiAtriai and VentricuiarExpreasionof
Myocardiai Brain-Natriuretic-Peptide During
Progressive Experiments Heart Faiiure
A. Luchner,T.L. Stevens, D.D. Borgeson, M.M. Redfield, C.-M. Wei,
J.G. Porter, J.C. Burnett, Jr. Carrfiorena/ResearchLaboratoryMayoClinic,
Rocheste&MN,USA
Although Brain-Natriuretic-Peptida (BNP) of myoesrdial origin is important in
cardiovascular and ranal function and as a marker of cardiac dysfunction, the
expression of BNP in atrial and ventricular rrryocardium in congestive heart
failure (CHF) remains controversial. We therefore determined left atrial (LA)
and left ventricular (LV) gene expression and tissue mncentration as well as
circulating BNP during the evolution of rapid ventricular pacing-induced CHF
in the dog (n = 15). Experimental Aeymptomatic LV Dyafunotion (ALVD, day
10 of pacing) was characterized by impaired LVfunction (EF31.8 & 3.0% vs.
normal 52.4 + 1.7, p c 0.03) but maintained arterial presaure (MAP 108 +
3 mmHg vs. normal 109 + 8, p = n.s.) and overt CHF (day 38) by further
